Trials / Completed
CompletedNCT02005783
Study of Danggui Buxue Decoction in Preventing Neutropenia
Adjuvant Treatment of EC/TC Versus EC/TC Plus Danggui Buxue Decoction in Breast Cancer：A Prospective, Randomized Trial
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 50 (estimated)
- Sponsor
- Shanghai Jiao Tong University School of Medicine · Academic / Other
- Sex
- Female
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
To evaluate EC/TC (epirubicin and cyclophosphomide or docetaxel and cyclophosphomide) with EC/TC plus DBD (Danggui Buxue Decoction) in adjuvant treatment of breast cancer patients. The aim is to evaluate whether DBD can decrease the incidence of grade 3/4 neutropenia induced by EC/TC regimen during chemotherapy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | DBD | DBD:one dose of medicine twice per day, orally |
| DRUG | Epirubicin | Epirubicin:90mg/m2, d1, q3w\*4 |
| DRUG | Cyclophosphamide | Cyclophosphamide:600mg/m2, d1, q3w\*4 |
| DRUG | Docetaxel | Docetaxel:75mg/m2, d1, q3w\*4 |
Timeline
- Start date
- 2013-10-01
- Primary completion
- 2015-08-01
- Completion
- 2015-10-01
- First posted
- 2013-12-09
- Last updated
- 2015-12-30
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT02005783. Inclusion in this directory is not an endorsement.